Information Provided By:
Fly News Breaks for June 1, 2015
MRTX
Jun 1, 2015 | 09:56 EDT
Piper Jaffray analyst Charles Duncan raised his price target for Mirati Therapeutics to $50 from $37 and reiterates an Overweight rating on the name. Duncan says Mirati's update on MGCD265 exceeded his expectations in terms of responses and number of patients. The stock is down 24%, or $8.98, to $27.68 in early trading.
News For MRTX From the Last 2 Days
There are no results for your query MRTX